Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

CME Clinical pharmacology (100626): self-assessment questionnaire

Andrew Webb and Tahseen A Chowdhury
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.16-5-486
Clin Med October 2016
Andrew Webb
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahseen A Chowdhury
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

SAQs and answers are ONLINE for RCP fellows and collegiate members

Format

Candidates are asked to choose the best answer from the five possible answers. This best of five format is used in many medical examinations, however the questions are not intended to be representative of those used in the MRCP(UK) Part 1 or Part 2 Written Examinations.

The answering process

  1. Go to www.rcplondon.ac.uk/SAQ

  2. Log on using your usual RCP username and password

  3. Select the relevant CME question paper

  4. Answer all 10 questions by selecting the best answer from the options provided

  5. Once you have answered all the questions, click on Submit

Registering your external CPD credits

Carrying out this activity allows you to claim two external CPD credits. These will be automatically transferred to your CPD diary, where you can review the activity and claim your points.

  1. A 75-year-old woman was reviewed in a general medical clinic. She was known to be hypertensive, had atrial fibrillation and chronic kidney disease stage 3. Her medication included aspirin, bendroflumethiazide, lisinopril, digoxin and atorvastatin.

    On examination her heart rate was 56 bpm, irregular and the average of three blood pressure measurements was 162/82 mmHg.

    What is the most appropriate further medicine to control her hypertension?

    1. amlodipine

    2. bisoprolol

    3. doxazosin

    4. spironolactone

    5. verapamil.

  2. A 47-year-old woman with alcohol dependence was admitted with a 3-day history of increasing abdominal pain and nausea. Her medications were amlodipine 10 mg orally daily and thiamine 50 mg orally daily. She admitted to drinking around one bottle of vodka per day but denied any intake over the preceding 3 days.

    On examination she was apyrexial, had a regular heart rate of 100 bpm and blood pressure 120/84 mmHg. She was jaundiced, irritable and had a marked tremor of the hands. Abdominal examination revealed 4 cm tender hepatomegaly with no clinical evidence of ascites. Her memory was poor and she was disorientated in time and place.

    Investigations

    Na+ 131 mmol/L (137–144), K+ 3.6 mmol/L (3.5–4.9), U 2.1 mmol/L (2.5–7.0), Cr 56 μmol/L (60–110), plasma glucose 5.3 mmol/L, albumin 26 g/L (37–49), bilirubin 80 μmol/L (1–22), ALT 345 U/L (5–35), ALP 164 U/L (45–105).

    Which of the following options would be the best treatment at this stage?

    1. enoxaparin 40 mg (4000 units) SC daily

    2. glucose 5% 500 mL with 10 mmol KCl IV over 4 hours

    3. lorazepam 1 mg IV over 2 minutes

    4. pabrinex® I/V High Potency by IV infusion over 30 minutes

    5. sodium chloride 0.9% 1 L with 20 mmol KCl IV over 2 hours.

  3. Which of the following is considered an implicit indicator of potentially inappropriate prescribing?

    1. any duplicate drug class prescription

    2. COX-2 selective NSAIDs with concurrent cardiovascular disease

    3. digoxin for heart failure with preserved systolic ventricular function

    4. levodopa or dopamine agonists for benign essential tremor

    5. ticlopidine in any circumstances.

  4. Which of the following medications is most commonly prescribed in UK primary care?

    1. antimicrobials

    2. cardiovascular

    3. gastrointestinal

    4. musculoskeletal

    5. skin.

  5. Which four groups of medicines are linked to around 50% of preventable drug-related admissions according to Howard et al?

    1. antiplatelets, anticoagulants, insulin and nonsteroidal anti-inflammatory drugs (NSAIDs)

    2. antiplatelets, diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs) and anticoagulants

    3. insulin, anticoagulants, monoclonal antibodies and antiplatelets

    4. nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelets, insulin and anticoagulants

    5. nonsteroidal anti-inflammatory drugs (NSAIDs), monoclonal antibodies, anticoagulants and diuretics.

  6. According to Barber et al, what percentage of patients are non-adherent to their new medicines 10 days after starting them?

    1. 10%

    2. 22%

    3. 34%

    4. 43%

    5. 55%.

  7. In general, angiotensin converting enzyme (ACE) inhibitors are preferred to angiotensin receptor blockers (ARBs) in the treatment of heart failure. Why, then, is the recently approved neprilysin inhibitor sacubitril combined with the ARB valsartan?

    1. better efficacy

    2. better pharmaco-economics

    3. ease of administration

    4. less frequently dosed

    5. less severe side effects, including angioedema.

  8. How many of the 91 medicines approved in 2015 are characterised by a novel mechanism of action?

    1. 4%

    2. 16%

    3. 25%

    4. 33%

    5. 36%.

  9. Which one of the following statements is correct regarding reports to the Yellow Card Scheme?

    1. A black triangle identifies new drugs that are being intensively monitored by regulators

    2. A suspected adverse drug reaction (ADR) as a result of a licensed medicine can be reported to the scheme, and those to unlicensed medicines reported directly to the manufacturer

    3. All suspected reactions to all drugs should be reported to the scheme

    4. Reports for ADRs associated with herbal medicines and vaccines are exempt from the scheme

    5. The reporter of the ADR must be a registered healthcare practitioner.

  10. A 55-year-old man of African-Caribbean race was seen in a hypertension clinic. He had been on therapy with felodipine 2.5 mg daily and enalapril 10 mg daily for several years. A week before the appointment he suffered an episode of severe lip swelling after a routine dental appointment. The swelling disappeared after a few hours and the patient assumed that it was a reaction to one of the dental products. He refused to go to the emergency department even though he told his wife that he felt as though he was choking. The clinic doctor suspects that the patient is describing an episode of ACE inhibitor-induced angioedema.

    Which of the following statements is true?

    1. As the angioedema has resolved, no change in antihypertensive treatment is needed

    2. The adverse effect has resolved despite continuing the drug therefore the angioedema is unlikely to be drug induced

    3. The adverse effect is unlikely to have been caused by the enalapril as the patient has been on treatment for several years

    4. The clinic doctor should report the ADR on a Yellow Card based on the suspicion of a serious reaction

    5. The patient's ethnicity has no significance to the probability of this being an ADR.

CME Movement disorders SAQ

Answers to the CME SAQ published in Clinical Medicine in August 2016

Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10

(e) (b) (c) (b) (c) (e) (b) (b) (c) (b)

  • © Royal College of Physicians 2016. All rights reserved.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
CME Clinical pharmacology (100626): self-assessment questionnaire
Andrew Webb, Tahseen A Chowdhury
Clinical Medicine Oct 2016, 16 (5) 486-487; DOI: 10.7861/clinmedicine.16-5-486

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CME Clinical pharmacology (100626): self-assessment questionnaire
Andrew Webb, Tahseen A Chowdhury
Clinical Medicine Oct 2016, 16 (5) 486-487; DOI: 10.7861/clinmedicine.16-5-486
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The epidemiology of polypharmacy
  • The need for a prescribing competency framework to address the burden of complex polypharmacy among multiple long-term conditions
Show more CME Clinical Pharmacology

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians